AI
ACRS icon

Axiom Investors’s Aclaris Therapeutics ACRS Stock Holding History

Axiom Investors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-47,580
Closed -$834K – 143
2018
Q1 		$834K Sell
47,580
-4,765
-9% -$101K 0.02% 143
2017
Q4 		$1.29M Sell
52,345
-19,089
-27% -$465K 0.03% 131
2017
Q3 		$1.84M Buy
71,434
+1,326
+2% +$35.5K 0.04% 123
2017
Q2 		$1.9M Buy
70,108
+2,641
+4% +$71.8K 0.05% 122
2017
Q1 		$2.01M Buy
+67,467
New +$1.95M 0.05% 120

Other funds holding ACRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Axiom Investors's ACRS Position: Q2 2018 in Review

Axiom Investors sold out of Aclaris Therapeutics (ACRS) in Q2 2018, closing a stake of 47,580 shares — an estimated $834K sold.

Axiom Investors first reported a position in ACRS in Q1 2017 and held it in 5 quarters. The position peaked at $2.01M in Q1 2017. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2018.

  • Axiom Investors reported no remaining Aclaris Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Axiom Investors sold 47,580 Aclaris Therapeutics shares in Q2 2018, an estimated $834K.
  • Axiom Investors first reported a position in Aclaris Therapeutics in Q1 2017 and held it in 5 quarters.
  • Axiom Investors's Aclaris Therapeutics position peaked at $2.01M in Q1 2017.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2018.

Based on Axiom Investors's 13F filing for Q2 2018, filed 13 Aug 2018.